Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

BioLife Solutions first-quarter revenue up 36% to $513,000

BioLife Solutions, Inc., announced today that Chairman and Chief Executive Officer Mike Rice issued the following letter to shareholders providing a general corporate update.

20 May 2010

STAAR Surgical receives CE Mark approval for product improvements to Visian Implantable Collamer Lens

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced CE Mark approval for a range of product improvements to the Company's Visian Implantable Collamer® Lens (ICL™) that more than doubles the current Visian addressable market in Europe.

20 May 2010

Stryker resolves FDA Warning Letters

Stryker Corporation today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the actions undertaken to address issues raised in two Warning Letters received in 2007 and 2009 are sufficient.

From Stryker 20 May 2010

Apotex launches generic Lipitor

Apotex Inc, a Canadian owned pharmaceutical company with headquarters in Toronto, launched today Apo-Atorvastatin, a generic version of 'Lipitor(R)' produced by Pfizer(R). This is the largest product to be genericized in Canadian history with approximate yearly sales of $1.2 billion. This last patent on Lipitor(R) will not expire until 2022. Apotex Inc. invented its own crystal form, thus overcoming the patents, 12 years ahead of time, which will result in close to $7 billion of cost-savings for the Canadian healthcare system.

20 May 2010

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inviragen has announced the initiation of the first clinical trial of its vaccine to protect against dengue fever. The trial, to be conducted at Saint Louis University, is designed to assess the safety of Inviragen's investigational dengue vaccine.

20 May 2010

Inova Labs completes $10 million Series A Preferred Stock financing

Inova Labs, Inc. of Austin, Texas announced today the closing of the private placement of shares of its Series A Preferred Stock. The placement went to investment funds affiliated with Three Arch Partners, based in Silicon Valley, California. Inova received gross proceeds of $10.0 million from the equity financing, which will be used for nationwide and international sales expansion of its LifeChoice® portable oxygen concentrator product line, continuation of next stage developments, and working capital.

20 May 2010

BioTeknica, AccuReg help companies achieve realistic FDA compliance goals

Every year, the Food and Drug Administration (FDA), asks hundreds of life science companies to improve their design and manufacturing systems – or risk receiving the ultimate penalty – a Consent Decree; whereby a company must remove its products from the marketplace. It's not easy to navigate FDA regulations because they aren't always "black and white" – in fact; they're often "gray" and open to interpretation depending upon the circumstances.

19 May 2010

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Four new projects, announced today, will develop biological methods that offer a new approach to antibiotic production, power generation for extremely small mechanical components, new classes of medicines and innovative techniques to study cell biology.

19 May 2010

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Discovery Laboratories, Inc. announces today that the revalidation of its optimized fetal rabbit Biological Activity Test (BAT, an important quality control release and stability test) has been completed, having met all pre-specified acceptance criteria.

19 May 2010

Aerocrine acquires all business, intellectual property assets of Apieron

Aerocrine AB today announced that it has acquired all business assets and intellectual property assets from the bankruptcy estate of Apieron Inc. As a result, Apieron's litigation against Aerocrine in the U.S. and Germany will be terminated and dismissed. Aerocrine's patent infringement claims in the U.S. against Apieron's estate will not be dismissed, however.

19 May 2010

Parents ignore emotional suffering overweight kids experience as teens

Millions of kids who are obese will likely suffer from verbal abuse, societal ostracization, stigmas, health problems and eventually die at a young age. The double calamity will occur if parents continue to avoid the problem and ignore the cries for help from our children, declares Dr. Sasson Moulavi, M.D., founder of the Smart for Life(R) Cookie Diet and its children's lifestyle program THIN ADVENTURE(TM).

19 May 2010

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

KemPharm, Inc. today announced that it has entered into an exclusive Supply Agreement with Johnson Matthey Inc., for the manufacture of the active pharmaceutical ingredient (API), KP201, KemPharm's novel hydrocodone prodrug for acute pain. KP201 was identified utilizing KemPharm's proprietary ligand activated therapy (LAT) approach.

18 May 2010

Simcere Pharmaceutical first-quarter total revenue up 3.7% to $67.2 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended March 31, 2010.

18 May 2010

Caliper to sell RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5M

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.

18 May 2010

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

VBI researchers establish new tree of life for gamma-proteobacteria

A new "tree of life" has been constructed by researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech for the gamma-proteobacteria, a large group of medically and scientifically important bacteria that includes Escherichia coli, Salmonella typhimurium, and other disease-causing organisms.

18 May 2010

Sonova Group financial year 2009/10 sales increase 20.1% to CHF 1,500.3 million

The Sonova Group increased its sales in financial year 2009/10 to CHF 1,500.3 million from CHF 1,249.2 million, thus posting an excellent growth rate of 20.1% in Swiss francs, despite a negative currency effect of 3.7%. The Group achieved organic growth of 18.4% in local currencies, which significantly surpassed the market as a whole. Market growth in 2009/10 is estimated at around 4% in units sold.

18 May 2010

Echo Therapeutics first-quarter net loss increases to $1.9 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced financial results for the period ended March 31, 2010.

18 May 2010

BioPharm Asia first-quarter revenues increase 41.6% to $32.1 million

BioPharm Asia, Inc., a producer, distributor and retailer of medical products in China, today announced its financial results for the first quarter ended March 31, 2010.

18 May 2010

WaferGen Biosystems first-quarter revenues increase to $389,785

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.

17 May 2010

Manufacturing News and Research

Further Reading

BioLife Solutions first-quarter revenue up 36% to $513,000

STAAR Surgical receives CE Mark approval for product improvements to Visian Implantable Collamer Lens

Stryker resolves FDA Warning Letters

Apotex launches generic Lipitor

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inova Labs completes $10 million Series A Preferred Stock financing

BioTeknica, AccuReg help companies achieve realistic FDA compliance goals

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Aerocrine acquires all business, intellectual property assets of Apieron

Parents ignore emotional suffering overweight kids experience as teens

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

Simcere Pharmaceutical first-quarter total revenue up 3.7% to $67.2 million

Caliper to sell RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5M

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

VBI researchers establish new tree of life for gamma-proteobacteria

Sonova Group financial year 2009/10 sales increase 20.1% to CHF 1,500.3 million

Echo Therapeutics first-quarter net loss increases to $1.9 million

BioPharm Asia first-quarter revenues increase 41.6% to $32.1 million

WaferGen Biosystems first-quarter revenues increase to $389,785

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News